PMDA drug package insert
アゼルニジピン錠8mg「BMD」
PMDA Prescription drug · 株式会社ビオメディクス · package insert Aug 25, 2026
Key facts
| Brand names | アゼルニジピン錠8mg「BMD」, アゼルニジピン錠16mg「BMD」 |
|---|---|
| Nonproprietary names | アゼルニジピン |
| Companies | 製造販売元／株式会社ビオメディクス |
| Product type | Prescription drug |
| Therapeutic category | 持続性Ca拮抗剤 |
| Therapeutic category codes | 872149 |
| YJ codes | 2149043F1143, 2149043F2140 |
| Approval numbers | 22500AMX00263000, 22500AMX00264000 |
| Package insert edition | 第5版 |
| Package insert date | Aug 25, 2026 |
| PMDA document key | 650208_2149043F1143_1 |
| PMDA company code | 650208 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: